{"id":45296,"date":"2026-07-27T16:00:00","date_gmt":"2026-07-27T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7d0a6e39db719216452afd0e89200412"},"modified":"2026-07-27T16:00:00","modified_gmt":"2026-07-27T14:00:00","slug":"liberate-bio-appoints-steven-h-bernstein-m-d-as-chief-medical-officer-to-advance-in-vivo-cell-programming-toward-the-clinic","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=45296","title":{"rendered":"Liberate Bio Appoints Steven H. Bernstein, M.D., as Chief Medical Officer to Advance In Vivo Cell Programming Toward the Clinic"},"content":{"rendered":"

\nCell therapy and translational medicine leader joins as the company\u2019s lead in vivo CAR-M programs approach first-in-human studies.<\/i><\/p><\/a><\/a>

BOSTON--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company developing genetic medicines that program immune cells directly inside the body, today announced the appointment of Steven H. Bernstein, M.D., as Chief Medical Officer, effective July 13, 2026.<\/p>

\nDr. Bernstein joins Liberate as the company advances its myeloid-selective, liver-detargeted lipid nanoparticle platform and lead in vivo<\/i> CAR-M programs toward first clinical evaluation. In this role, he will lead clinical development strategy, oversee execution of upcoming clinical studies, and translate early human data into registrational development plans. He will also guide the company\u2019s translational medicine strategy, including biomarker selection, clinical endpoint development, and integration of patient data to prioritize the pipeline.<\/p>

\n\u201cSteven is exactly the clinical leader Liberate needs at this moment,\u201d said Shawn P. Davis, Ph.D., Chief Executive Officer of Liberate Bio. \u201cWe have shown that monocytes and macrophages can be reprogrammed into therapeutic effector cells directly in vivo<\/i>, bringing the potency of engineered cell therapy to patients without the manufacturing and access constraints that have limited it. Steven\u2019s experience advancing cell therapies across the arc from early development through approval gives us the judgment to translate that biology into disciplined human studies and, ultimately, into medicines that reach far more patients.\u201d<\/p>

\nDr. Bernstein is a physician-scientist and biopharmaceutical executive with deep experience in clinical development, translational medicine, regulatory strategy, clinical operations, hematologic oncology, and engineered cell therapies. Most recently, he led Clinical Development, Translational Medicine, Regulatory Science, and Clinical Operations for the Cell Medicine Unit at Regeneron. Previously, he served as Chief Medical Officer at 2seventy bio, where he helped advance autologous cell therapy programs, including work related to Abecma, the first FDA-approved BCMA-directed CAR-T therapy for multiple myeloma. Earlier in his career, Dr. Bernstein held clinical and translational leadership roles at Turnstone Biologics and Bristol Myers Squibb and was an academic physician-scientist focused on lymphoma immunobiology and clinical investigation.<\/p>

\n\u201cLiberate has built a differentiated platform with the potential to bring cell therapy-like activity to far broader patient populations,\u201d said Steven H. Bernstein, M.D., Chief Medical Officer of Liberate Bio. \u201cBy programming monocytes and macrophages in vivo<\/i>, the company combines the potency of engineered immune cells with the repeatability and scalability of an RNA medicine. I\u2019m looking forward to translating this platform\u2019s results into clinical studies and development paths designed to demonstrate meaningful patient benefit.\u201d<\/p>

\nLiberate\u2019s proprietary RAPTOR\u2122 platform enables direct screening of lipid nanoparticles in non-human primates, generating in vivo<\/i> delivery datasets that guide both biological selection and AI-enabled LNP optimization. The company\u2019s lead LNPs are designed to selectively deliver RNA payloads to myeloid lineage cells while detargeting the liver and avoiding meaningful T-cell delivery. This delivery profile enables monocytes and macrophages to be programmed directly in vivo<\/i> as therapeutic effector cells, supporting Liberate\u2019s lead in vivo<\/i> CAR-M programs in autoimmune disease and oncology.<\/p>

\nAs previously reported, Liberate\u2019s lead in vivo<\/i> CAR-M approach has programmed monocytes directly in the circulation of non-human primates, producing up to 99% peripheral B-cell depletion at well-tolerated doses \u2014 providing preclinical evidence <\/i>that immune effector cells can be engineered inside the body rather than manufactured outside it. With Dr. Bernstein\u2019s appointment, Liberate is adding the clinical leadership required to select the optimal first indication, execute its initial human studies, and use early clinical data to shape the next stage of pipeline and registrational development.<\/p>

\nAbout Liberate Bio<\/b><\/p>

\nLiberate Bio is building the next generation of genetic medicines by solving the most fundamental challenge in the field: delivery beyond the liver. The company\u2019s proprietary RAPTOR\u2122 platform combines high-throughput in vivo<\/i> screening in non-human primates with AI-driven design and optimization, creating the first biological dataset powerful enough to train artificial intelligence on real delivery outcomes.<\/p>

\nUsing this feedback loop, Liberate Bio has engineered lipid nanoparticles that target specific immune and bone marrow\u2013resident cell types, including monocytes, macrophages, and hematopoietic stem cells (HSCs). This approach enables the programmable delivery of mRNA, gene editing, and other payloads directly to the cells that drive disease \u2014 unlocking the potential to treat oncology, autoimmune, and rare genetic disorders from within the body.<\/p>

\nLiberate Bio\u2019s first programs focus on in vivo<\/i> CAR-M therapies to reprogram immune cells safely and at scale. Longer term, the company\u2019s platform provides a foundation for a new class of AI-informed, systemically delivered genetic medicines that extend to multiple organs and therapeutic areas.<\/p>

\nFor more information about the company\u2019s technologies, team, and mission, visit www.liberatebio.com<\/a>.<\/p> Contacts<\/b>

Shawn Davis\ninfo@liberatebio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Cell therapy and translational medicine leader joins as the company\u2019s lead in vivo CAR-M programs approach first-in-human studies.BOSTON–(BUSINESS WIRE)–Liberate Bio, Inc., a biotechnology company developing genetic medicines that program immune cel…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45296","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45296"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45296\/revisions"}],"predecessor-version":[{"id":45297,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45296\/revisions\/45297"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}